EMA: New Guideline on Development of Medicines for Paediatric Use
The European Medicines Agency has recently published a draft guideline on pharmaceutical development of medicines for paediatric use.
In January 2007 Regulation EC No 1901/2006 (the "Paediatric Regulation") entered into force. As a result of this Regulation, the number of paediatric formulations that the pharmaceutical industry will have to develop to support their clinical trials will increase. It is expected that the number of medicines applying for a marketing authorisation for paediatric use will increase as a result. Therefore, the existing regulatory documents need to be supported by specific regulatory guidance on the pharmaceutical development of medicines for use in children between birth and 18 years of age.
Please see the Guideline draft for further information.
Comments related to this draft should be provided using this template. The completed comments form should be sent to qwp@ema.europa.eu.
Please note that the deadline for comments for this draft guideline is 31 December 2011.
Related GMP News
10.02.2025FDA issues Draft Guidance on Handling Protocol Deviations in Clinical Trials
10.02.2025Further Progress in ICH's Global GMP Harmonization
22.01.2025Final ICH E6(R3) Guideline on GCP released
14.01.2025Swissmedic Position Paper on Clinical Trials
14.01.2025Annual Report of the GCP Inspectors' Working Group